Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Director Dealing

26 Apr 2013 12:21

RNS Number : 3522D
Advanced Oncotherapy PLC
26 April 2013
 



26 April 2013

 

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Director Dealing

 

Advanced Oncotherapy (AIM: AVO) announces that on 25 April 2013, Tim Lebus, Non-Executive Director, purchased two tranches of ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares"), the first tranche of 750,000 Ordinary Shares at a price of 1.56 pence per Ordinary Share. The second tranche of 213,000 Ordinary Shares was purchased at a price of 1.545 pence per Ordinary Share.

 

Following this purchase, Tim Lebus now holds 963,000 Ordinary Shares, representing approximately 0.37 per cent. of the issued share capital of Advanced Oncotherapy.

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 7569 9650

+44 20 7469 0930

+44 20 7920 3150

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBBGDSGDDBGXL
Date   Source Headline
4th Jul 20189:00 amRNSPrice Monitoring Extension
2nd Jul 20187:00 amRNSDirectorate Changes
27th Jun 20187:00 amRNSFinal Results
31st May 20187:00 amRNSUpdate on financing
29th May 20187:00 amRNSTechnological update
11th May 20184:35 pmRNSPrice Monitoring Extension
11th May 20187:00 amRNSUpdate on Distribution Agreement Payment
8th May 20187:00 amRNSUK assembly and testing site agreement
26th Apr 20181:50 pmRNSGPSL Research on Advanced Oncotherapy Plc
5th Apr 20187:00 amRNSHolding(s) in Company
3rd Apr 20189:43 amRNSUpdate on Distribution Agreement
12th Mar 20187:15 amRNSHardman & Co Research: Confidence greatly boosted
23rd Feb 20184:05 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSCompletion of the Subscription Agreement
23rd Jan 201811:48 amRNSResult of Meeting
12th Jan 20187:00 amRNSDirector dealing
28th Dec 20177:01 amRNSNotice of GM
28th Dec 20177:00 amRNSTechnological update
22nd Dec 201711:24 amRNSHolding(s) in Company
13th Dec 20174:25 pmRNSHolding(s) in Company
11th Dec 20172:02 pmRNSHardman Res.: Distribution deal & capital increase
7th Dec 20177:00 amRNSDistribution agreement and Equity Investments
29th Sep 20177:00 amRNSHalf-year Report
4th Sep 20177:00 amRNSTechnological update
1st Aug 20177:00 amRNSDirector Dealing
31st Jul 20177:00 amRNSTechnological milestones update - CCL units
19th Jul 20173:56 pmRNSResult of AGM
19th Jul 201710:16 amRNSFinancing facility by significant shareholders
5th Jul 20177:00 amRNSVideo and update on progress at Harley Street
26th Jun 20177:00 amRNSFinal Results
21st Jun 20177:00 amRNSConversion of Convertible Loan Notes
14th Jun 20177:00 amRNSAppointment of Senior VP of Medical Physics
13th Jun 20177:00 amRNSAdditional financing agreement and new appointment
12th Jun 20177:00 amRNSTechnological milestones update
5th Jun 20172:45 pmRNSUpdate on Bracknor financing
31st May 20174:41 pmRNSHolding(s) in Company
30th May 20177:00 amRNSHarley Street construction update
26th May 20176:23 pmRNSConversion of Convertible Loan Notes
26th May 20177:00 amRNSUpdate on Bracknor financing
24th May 20177:13 amRNSConversion of convertible loan notes
23rd May 201712:01 pmRNSHolding(s) in Company
18th May 20177:31 amRNSConversion of convertible loan notes
16th May 20179:02 amRNSConversion of loan notes
15th May 20171:01 pmRNSDirector Dealing
11th May 20177:00 amRNSDirector Dealing
8th May 20177:00 amRNSIssue of Equity & Director Shareholding
4th May 20177:05 amRNSHolding(s) in Company
3rd May 20171:29 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSUpdate on Bracknor financing
26th Apr 201711:18 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.